AstraZeneca plc (NYSE:AZN) Expected to Post Quarterly Sales of $6.53 Billion
Analysts forecast that AstraZeneca plc (NYSE:AZN) will post $6.53 billion in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for AstraZeneca’s earnings. AstraZeneca reported sales of $6.41 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 1.9%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Thursday, November 5th.
On average, analysts expect that AstraZeneca will report full year sales of $26.31 billion for the current financial year, with estimates ranging from $26.05 billion to $26.48 billion. For the next fiscal year, analysts forecast that the company will post sales of $29.93 billion, with estimates ranging from $28.65 billion to $30.76 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover AstraZeneca.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.44 by $0.04. The business had revenue of $6.28 billion for the quarter, compared to analysts’ expectations of $6.27 billion. AstraZeneca had a net margin of 8.36% and a return on equity of 37.72%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS.
A number of hedge funds have recently made changes to their positions in the business. Sanders Morris Harris LLC lifted its stake in AstraZeneca by 16.5% in the 3rd quarter. Sanders Morris Harris LLC now owns 13,600 shares of the company’s stock valued at $744,000 after purchasing an additional 1,930 shares during the last quarter. Mission Wealth Management LP acquired a new stake in shares of AstraZeneca in the third quarter valued at approximately $205,000. Vigilant Capital Management LLC lifted its position in shares of AstraZeneca by 3.1% in the third quarter. Vigilant Capital Management LLC now owns 341,550 shares of the company’s stock valued at $18,717,000 after buying an additional 10,385 shares during the last quarter. Evolution Wealth Advisors LLC boosted its stake in shares of AstraZeneca by 157.3% during the 3rd quarter. Evolution Wealth Advisors LLC now owns 7,953 shares of the company’s stock worth $436,000 after acquiring an additional 4,862 shares during the period. Finally, Coastline Trust Co increased its holdings in shares of AstraZeneca by 24.7% during the 3rd quarter. Coastline Trust Co now owns 7,019 shares of the company’s stock worth $385,000 after acquiring an additional 1,389 shares during the last quarter. Hedge funds and other institutional investors own 16.30% of the company’s stock.
AZN opened at $53.03 on Friday. The company has a market capitalization of $139.18 billion, a price-to-earnings ratio of 63.89, a P/E/G ratio of 1.63 and a beta of 0.50. The business’s 50-day moving average price is $54.72 and its two-hundred day moving average price is $53.44. AstraZeneca has a 1 year low of $36.15 and a 1 year high of $64.94. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.82 and a quick ratio of 0.63.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.